Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myles Osborn

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Drug Discovery Today|October 17, 2025
The emerging role of fatty acid-binding protein 3 (FABP3) in cancerWilliam Warren, Myles Osborn, Andy Yates, et al.
Drug Discovery Today|April 13, 2024
The emerging role of fatty acid binding protein 7 (FABP7) in cancersWilliam George Warren, Myles Osborn, Andrew Yates, et al.
The Journal of Investigative Dermatology|April 10, 2025
ART26.12, an FABP5 Inhibitor, Shows Efficacy in Preclinical Psoriasis ModelsWilliam G Warren, Myles Osborn, Andrew Yates, et al.
European Journal of Pain (London, England)|April 15, 2026
Evaluating FABP5 as a Therapeutic Target for Pain ManagementWilliam Warren, Myles Osborn, Martin Kaczocha, et al.
Toxicology and Applied Pharmacology|September 1, 2024
Potential safety implications of fatty acid-binding protein inhibitionWilliam G Warren, Myles Osborn, Paul Duffy, et al.
Drug Discovery Today|May 25, 2023
The emerging role of fatty acid binding protein 5 (FABP5) in cancersWilliam George Warren, Myles Osborn, Andy Yates, et al.
The Journal of Pain|January 17, 2024
Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral NeuropathyGeorge Warren, Myles Osborn, Christopher Tsantoulas, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Drug Discovery Today|October 17, 2025
The emerging role of fatty acid-binding protein 3 (FABP3) in cancerWilliam Warren, Myles Osborn, Andy Yates, et al.
Drug Discovery Today|April 13, 2024
The emerging role of fatty acid binding protein 7 (FABP7) in cancersWilliam George Warren, Myles Osborn, Andrew Yates, et al.
The Journal of Investigative Dermatology|April 10, 2025
ART26.12, an FABP5 Inhibitor, Shows Efficacy in Preclinical Psoriasis ModelsWilliam G Warren, Myles Osborn, Andrew Yates, et al.
European Journal of Pain (London, England)|April 15, 2026
Evaluating FABP5 as a Therapeutic Target for Pain ManagementWilliam Warren, Myles Osborn, Martin Kaczocha, et al.
Toxicology and Applied Pharmacology|September 1, 2024
Potential safety implications of fatty acid-binding protein inhibitionWilliam G Warren, Myles Osborn, Paul Duffy, et al.
Drug Discovery Today|May 25, 2023
The emerging role of fatty acid binding protein 5 (FABP5) in cancersWilliam George Warren, Myles Osborn, Andy Yates, et al.
The Journal of Pain|January 17, 2024
Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral NeuropathyGeorge Warren, Myles Osborn, Christopher Tsantoulas, et al.
Pageof 1